BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment

Jing-Yu Lang,Jennifer L Hsu,Funda Meric-Bernstam,Chun-Ju Chang,Qingfei Wang,Yi Bao,Hirohito Yamaguchi,Xiaoming Xie,Wendy A Woodward,Dihua Yu,Gabriel N Hortobagyi,Mien-Chie Hung

DOI: https://doi.org/10.1016/j.ccr.2011.07.017

IF: 50.3

2011-09-13

Cancer Cell

Abstract:Breast cancer initiating cells (BCICs), which can fully recapitulate the tumor origin and are often resistant to chemo- and radiotherapy, are currently considered as a major obstacle for breast cancer treatment. Here, we show that BIKDD, a constitutively active mutant form of proapoptotic gene, BIK, effectively induces apoptosis of breast cancer cells and synergizes with lapatinib. Most importantly, BikDD significantly reduces BCICs through co-antagonism of its binding partners Bcl-2, Bcl-xL, and Mcl-1, suggesting a potential therapeutic strategy targeting BCICs. Furthermore, we developed a cancer-specific targeting approach for breast cancer that selectively expresses BikDD in breast cancer cells including BCICs, and demonstrated its potent antitumor activity and synergism with lapatinib in vitro and in vivo.